Clinical commissioning policy: Pembrolizumab in combination with dabrafenib and trametinib for patients with BRAF mutated anaplastic thyroid cancer (adults)

Document first published:
Page updated:
Topic:
Publication type:

Pembrolizumab in combination with dabrafenib and trametinib is not recommended to be available as a routine commissioning treatment option for adults with BRAF mutated anaplastic thyroid cancer.

Document

Clinical commissioning policy: Pembrolizumab in combination with dabrafenib and trametinib for patients with BRAF mutated anaplastic thyroid cancer (adults)

Clinical commissioning policy: Pembrolizumab in combination with dabrafenib and trametinib for patients with BRAF mutated anaplastic thyroid cancer (adults)

  • PDF
  • 205 KB
  • 5 pages

Summary

Published 16 July 2026.